MX362675B - Antagonistas de receptores de péptido liberadores de gastrina para la detección, diagnóstico y tratamiento de cáncer positivo a receptores de péptido liberadores de gastrina. - Google Patents

Antagonistas de receptores de péptido liberadores de gastrina para la detección, diagnóstico y tratamiento de cáncer positivo a receptores de péptido liberadores de gastrina.

Info

Publication number
MX362675B
MX362675B MX2015003772A MX2015003772A MX362675B MX 362675 B MX362675 B MX 362675B MX 2015003772 A MX2015003772 A MX 2015003772A MX 2015003772 A MX2015003772 A MX 2015003772A MX 362675 B MX362675 B MX 362675B
Authority
MX
Mexico
Prior art keywords
gastrine
liberating
receptors
antigonists
diagnosis
Prior art date
Application number
MX2015003772A
Other languages
English (en)
Spanish (es)
Other versions
MX2015003772A (es
Inventor
Theodosia Maina-Nock
Berthold Artur Nock
Jong Hendriks Marion De
Original Assignee
Advanced Accelerator Applications Usa Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Advanced Accelerator Applications Usa Inc filed Critical Advanced Accelerator Applications Usa Inc
Publication of MX2015003772A publication Critical patent/MX2015003772A/es
Publication of MX362675B publication Critical patent/MX362675B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/008Peptides; Proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
MX2015003772A 2012-09-25 2013-09-25 Antagonistas de receptores de péptido liberadores de gastrina para la detección, diagnóstico y tratamiento de cáncer positivo a receptores de péptido liberadores de gastrina. MX362675B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261705513P 2012-09-25 2012-09-25
PCT/US2013/061712 WO2014052471A1 (en) 2012-09-25 2013-09-25 Grpr-antagonists for detection, diagnosis and treatment of grpr-positive cancer

Publications (2)

Publication Number Publication Date
MX2015003772A MX2015003772A (es) 2015-11-09
MX362675B true MX362675B (es) 2019-01-30

Family

ID=49887190

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015003772A MX362675B (es) 2012-09-25 2013-09-25 Antagonistas de receptores de péptido liberadores de gastrina para la detección, diagnóstico y tratamiento de cáncer positivo a receptores de péptido liberadores de gastrina.

Country Status (19)

Country Link
US (7) US9839703B2 (https=)
EP (2) EP2900279B1 (https=)
JP (4) JP6562838B2 (https=)
KR (2) KR102190005B1 (https=)
AU (4) AU2013323596C1 (https=)
BR (1) BR112015006453B1 (https=)
CA (2) CA3114832A1 (https=)
DK (1) DK2900279T3 (https=)
ES (1) ES2745635T3 (https=)
HR (1) HRP20191620T1 (https=)
HU (1) HUE045724T2 (https=)
IL (4) IL276300B2 (https=)
LT (1) LT2900279T (https=)
MX (1) MX362675B (https=)
PL (1) PL2900279T3 (https=)
PT (1) PT2900279T (https=)
RU (1) RU2693465C9 (https=)
SI (1) SI2900279T1 (https=)
WO (1) WO2014052471A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2841238C (en) * 2011-07-08 2019-10-01 Biosynthema Inc. Enhanced in vivo targeting of radiolabelled peptides with the means of enzyme inhibitors
ES2745635T3 (es) 2012-09-25 2020-03-03 Advanced Accelerator Applications Usa Inc Antagonistas de GRPR para la detección, diagnóstico y tratamiento del cáncer positivo para GRPR
EP3015462A1 (en) * 2014-10-29 2016-05-04 OctreoPharm Schiences GmbH Enantiopure chelating agents for chelator coupled pharmaceuticals, corresponding preparation method thereof and chelator coupled pharmaceuticals
EP3101012A1 (en) 2015-06-04 2016-12-07 Bayer Pharma Aktiengesellschaft New gadolinium chelate compounds for use in magnetic resonance imaging
US11857352B2 (en) 2016-09-06 2024-01-02 The Research Foundation For The State University Of New York Positron imaging tomography imaging agent composition and method for bacterial infection
ES2814555T3 (es) 2016-11-28 2021-03-29 Bayer Pharma AG Compuestos de quelato de gadolinio con alta relaxividad para usar en la obtención de imágenes por resonancia magnética
HRP20231458T1 (hr) 2017-01-12 2024-05-10 Radiomedix Inc. Liječenje stanica raka koje prekomjerno eksprimiraju receptore za somatostatin primjenom derivata oktreotida keliranih sa radioizotopima
CA3112060A1 (en) * 2018-10-12 2020-04-16 Advanced Accelerator Applications International Sa Pharmaceutical composition comprising a radiolabeled gprp antagonist and a surfactant
WO2021068051A1 (en) * 2018-11-13 2021-04-15 Provincial Health Services Authority Radiolabeled bombesin-derived compounds for in vivo imaging of gastrin-releasing peptide receptor (grpr) and treatment of grpr-related disorders
KR102934987B1 (ko) 2018-11-23 2026-03-09 바이엘 악티엔게젤샤프트 조영 매체의 제형 및 그의 제조 방법
KR20220063218A (ko) * 2019-09-16 2022-05-17 노파르티스 아게 안정한 농축 방사성 약제학적 조성물
TWI878344B (zh) * 2019-09-17 2025-04-01 瑞士商諾華公司 放射性標記grpr拮抗劑之方法及其套組
JP2022549258A (ja) * 2019-09-24 2022-11-24 ノバルティス アーゲー セラノスティックスとして使用するための放射性標識grprアンタゴニスト
CA3153267A1 (en) * 2019-12-19 2021-06-24 Hans-Jurgen Wester Modified grpr antagonist peptides for imaging and therapy of cancer
AU2023239751A1 (en) 2022-03-25 2024-09-05 Provincial Health Services Authority Radiolabeled compounds for in vivo imaging of gastrin-releasing peptide receptor (grpr) and treatment of grpr-related disorders
WO2026083422A1 (en) * 2024-10-20 2026-04-23 Starget Pharma Ltd Cyclic grpr binding peptides

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5019647A (en) * 1988-05-24 1991-05-28 Merck & Co., Inc. Gastrin releasing peptide antagonist
US4943561A (en) * 1988-11-28 1990-07-24 Merck & Co., Inc. Gastrin releasing peptide antagonist
US5028692A (en) 1989-04-25 1991-07-02 Merck & Co., Inc. Gastrin releasing peptide antagonist
IE903958A1 (en) 1989-11-06 1991-05-08 Erba Carlo Spa Reduced irreversible bombesin antagonists
WO1993016105A1 (en) 1992-02-07 1993-08-19 Merrell Dow Pharmaceuticals Inc. Phenylalanine analogs of bombesin
US5620955A (en) * 1993-06-18 1997-04-15 Peptide Technologies Corporation Bombesin receptor antagonists and uses thereof
EP1033372A4 (en) 1997-11-18 2000-10-04 Chugai Pharmaceutical Co Ltd COMPOSITIONS WITH ANTI-TUMOR ACTIVITY
JP5139678B2 (ja) 2003-07-24 2013-02-06 ブラッコ・イメージング・ソシエタ・ペル・アチオニ 安定な放射性医薬品組成物およびその製法
EP2100900A1 (en) 2008-03-07 2009-09-16 Universitätsspital Basel Bombesin analog peptide antagonist conjugates
IN2013MN01188A (https=) 2010-11-22 2015-07-10 Piramal Imaging Sa
CA2841238C (en) * 2011-07-08 2019-10-01 Biosynthema Inc. Enhanced in vivo targeting of radiolabelled peptides with the means of enzyme inhibitors
ES2745635T3 (es) * 2012-09-25 2020-03-03 Advanced Accelerator Applications Usa Inc Antagonistas de GRPR para la detección, diagnóstico y tratamiento del cáncer positivo para GRPR

Also Published As

Publication number Publication date
AU2013323596B2 (en) 2018-03-22
EP2900279B1 (en) 2019-08-14
JP6562838B2 (ja) 2019-08-21
AU2019216714A1 (en) 2019-09-05
KR102190005B1 (ko) 2020-12-15
WO2014052471A1 (en) 2014-04-03
KR102314293B1 (ko) 2021-10-19
RU2015115529A (ru) 2016-11-20
IL312551A (en) 2024-07-01
JP7534498B2 (ja) 2024-08-14
US12064490B2 (en) 2024-08-20
SI2900279T1 (sl) 2019-12-31
AU2013323596C1 (en) 2020-10-15
IL276300A (en) 2020-09-30
US20200009276A1 (en) 2020-01-09
ES2745635T3 (es) 2020-03-03
CA2886068C (en) 2021-06-22
IL237844B (en) 2018-01-31
BR112015006453A2 (https=) 2017-09-05
IL276300B2 (en) 2024-10-01
JP2019167365A (ja) 2019-10-03
US11083805B2 (en) 2021-08-10
AU2019216714B2 (en) 2021-04-08
US20220008568A1 (en) 2022-01-13
US20180133349A1 (en) 2018-05-17
JP7358430B2 (ja) 2023-10-10
AU2013323596A1 (en) 2015-04-02
US20240366812A1 (en) 2024-11-07
AU2021201914A1 (en) 2021-04-29
EP2900279A1 (en) 2015-08-05
EP3536347A1 (en) 2019-09-11
KR20150090886A (ko) 2015-08-06
CA2886068A1 (en) 2014-04-03
JP2021191800A (ja) 2021-12-16
JP2023126440A (ja) 2023-09-07
LT2900279T (lt) 2019-11-11
US9839703B2 (en) 2017-12-12
HUE045724T2 (hu) 2020-01-28
KR20200139846A (ko) 2020-12-14
IL312551B2 (en) 2025-12-01
US12064489B2 (en) 2024-08-20
MX2015003772A (es) 2015-11-09
RU2693465C2 (ru) 2019-07-03
US20150265732A1 (en) 2015-09-24
AU2018204513B2 (en) 2019-05-23
JP6997135B2 (ja) 2022-02-04
CA3114832A1 (en) 2014-04-03
IL256649A (en) 2018-02-28
RU2019119378A (ru) 2020-10-23
DK2900279T3 (da) 2019-09-30
US12064491B2 (en) 2024-08-20
AU2018204513C1 (en) 2020-10-15
RU2693465C9 (ru) 2020-08-14
JP2015533119A (ja) 2015-11-19
HRP20191620T1 (hr) 2019-12-13
IL256649B (en) 2020-08-31
IL312551B1 (en) 2025-08-01
IL276300B1 (en) 2024-06-01
PT2900279T (pt) 2019-10-14
AU2021201914B2 (en) 2024-09-05
BR112015006453B1 (pt) 2023-10-17
US20210346528A1 (en) 2021-11-11
PL2900279T3 (pl) 2020-05-18
US20210346529A1 (en) 2021-11-11
AU2018204513A1 (en) 2018-07-12

Similar Documents

Publication Publication Date Title
MX362675B (es) Antagonistas de receptores de péptido liberadores de gastrina para la detección, diagnóstico y tratamiento de cáncer positivo a receptores de péptido liberadores de gastrina.
WO2009129311A3 (en) Somatostatin receptor 2 antagonists
MY202336A (en) Agonist antibodies that bind human cd137 and uses thereof
UA111818C2 (uk) Антитіло проти csf-1r
MX2022002401A (es) Productos radiofarmaceuticos, agentes de radioimagenologia,y uso de los mismos.
CU20190056A7 (es) Ácidos carboxílicos de benzimidazoles y 4-aza, 5-aza, 7-aza y 4,7-diaza-benzimidazoles como agonistas receptores de glp-1, útiles para tratar o prevenir enfermedades cardiometabólicas
NZ700823A (en) Antibodies against claudin 18.2 useful in cancer diagnosis
BR112012016820A2 (pt) Metodos para tratamento de cancer de seio
CL2016000883A1 (es) Compuestos macrocíclicos, inhibidores de antígeno prostático específico de membrana (psma); composición farmacéutica; complejo de metal; y su uso para preparar compuestos radiomarcados útiles para la formación de imágenes para diagnosticar y para el tratamiento de cáncer de próstata y/o metástasis de la misma.
MY161136A (en) Liquid deodorant composition for textile products
MA40074A (fr) Composés liant ras multivalents
EP3906945A3 (en) Nucleic acids encoding human antibodies to sialyl-lewis a
UA115657C2 (uk) Виділене антитіло, яке зв'язується з одним або декількома епітопами тау, фармацевтична композиція, що його містить, спосіб лікування та спосіб діагностики хвороби альцгеймера на основі виділеного антитіла
NZ601793A (en) Methods and compositions for diagnosis and treatment of cancer
UA117096C2 (uk) Поліпептид, що зв'язується з c5 комплементу людини
EA201301334A1 (ru) Меченные радиоактивными изотопами ингибиторы глутаминилциклазы
NZ594480A (en) Methods and compositions for diagnosis and treatment of cancer
CR11396A (es) Nuevos anticuerpos especificos de los peptidos-b-amiloides y sus usos como agentes de diagnostico o drogas
AR088083A1 (es) USO DE ANTICUERPOS DE UNION A IL-1b
MX2022010809A (es) Antagonistas de integrina-beta7 para usarse en el tratamiento y diagnostico de trastornos inflamatorios gastrointestinales.
MX2015012528A (es) Inhibidores macrociclicos de cinasa inducibles por sal.
EP3988673A3 (en) Variants of tnfsf15 and dcr3 associated with crohn's disease
MY185593A (en) Cortistatin analogues for the treatment of inflammatory and/or immune diseases
EA201490790A1 (ru) Пептидные конъюгаты агониста рецептора гастрина и глюкагон подобного пептида 1
MX2022008951A (es) Composiciones de inhibidores de molecula peque?a del receptor de quimiocina c-c tipo 9 (ccr9) y anticuerpos bloqueadores anti- 4?7 integrina para usarse en el tratamiento de enfermedad inflamatoria de intestino.

Legal Events

Date Code Title Description
FG Grant or registration